Intranasal delivery, though less studied with Dihexa, would theoretically provide direct CNS access with minimal systemic exposure, potentially requiring the least frequent administration to maintain effective brain tissue concentrations
Hypothetically, these strategies could reduce the production of ROS and, therefore, block the release of second messengers and auto-antigens, thus eliminating a crucial trigger for the activation of the immune system
Tables 1 and 2 summarize passive membrane diffusion and active transport membrane permeability, respectively, for select small molecule NNMT inhibitors for which structure activity relationships had been previously developed.[17] 1-MNA, a product inhibitor of NNMT[12, 24, 25] exhibited no passive permeability (Table 1)
Xue, X., Li, L., Chen, X., Hu, S